MicroRNA‑338‑3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma

Tong,Zhigang; Meng,Xianfeng; Wang,Jinsong; Wang,Lixin

doi:10.3892/etm.2017.5169

MicroRNA‑338‑3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma

Authors:
- Zhigang Tong
- Xianfeng Meng
- Jinsong Wang
- Lixin Wang
View Affiliations

Affiliations: Department of Urinary Surgery, The Affiliated Hospital, Changchun University of Chinese Medicine, Changchun, Jilin 130021, P.R. China, Department of Medical Insurance, Jilin Academy of Chinese Medicine Sciences, Changchun, Jilin 130021, P.R. China
Published online on: September 21, 2017 https://doi.org/10.3892/etm.2017.5169
Pages: 5200-5206

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑338‑3p has been reported to be involved in tumor progression and development in various types of cancer. However, the biological function of miR‑338‑3p and its related molecular pathways involved in the progression of renal cell carcinoma (RCC) are unknown. The present study aimed to investigate the biological role and underlying mechanism of miR‑338‑3p in RCC cells. It was demonstrated that miR‑338‑3p expression level was significantly downregulated (P<0.05) in RCC tissues and cell lines. Clinical association analysis indicated that low expression of miR‑338‑3p was significantly associated with advanced TNM stage and lymph node metastasis (P<0.05). Function assays revealed that restoration of miR‑338‑3p in RCC cells significantly inhibited cell proliferation, colony formation, migration and invasion (P<0.05). Notably, sex‑determining region Y‑box 4 (SOX4) was identified as a direct target of miR‑338‑3p in RCC cells through a luciferase reporter assay, reverse transcription‑quantitative polymerase chain reaction and western blot analysis. Furthermore, SOX4 overexpression partially rescued miR‑338‑3p‑mediated inhibition of cell proliferation, colony formation, migration and invasion in RCC cells. These results suggested that miR‑338‑3p functioned as a tumor suppressor in RCC cells by modulating SOX4, suggesting that miR‑338‑3p may have a potential use in the treatment of RCC.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Pantuck AJ, Zisman A and Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol. 166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
3	Chow WH, Dong LM and Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
4	Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
7	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
8	Garzon R and Marcucci G: Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kurozumi A, Goto Y, Okato A, Ichikawa T and Seki N: Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma. J Hum Genet. 62:49–56. 2017. View Article : Google Scholar : PubMed/NCBI
10	Gu L, Li H, Chen L, Ma X, Gao Y, Li X, Zhang Y, Fan Y and Zhang X: MicroRNAs as prognostic molecular signatures in renal cell carcinoma: A systematic review and meta-analysis. Oncotarget. 6:32545–32560. 2015. View Article : Google Scholar : PubMed/NCBI
11	Huang XH, Chen JS, Wang Q, Chen XL, Wen L, Chen LZ, Bi J, Zhang LJ, Su Q and Zeng WT: miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol. 225:463–472. 2011. View Article : Google Scholar : PubMed/NCBI
12	Fu X, Tan D, Hou Z, Hu Z, Liu G, Ouyang Y and Liu F: The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation. PloS One. 7:e432042012. View Article : Google Scholar : PubMed/NCBI
13	Sun K, Deng HJ, Lei ST, Dong JQ and Li GX: miRNA-338-3p suppresses cell growth of human colorectal carcinoma by targeting smoothened. World J Gastroenterol. 19:2197–2207. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wen C, Liu X, Ma H, Zhang W and Li H: miR3383p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2. Int J Oncol. 46:2277–2285. 2015. View Article : Google Scholar : PubMed/NCBI
15	Li P, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, et al: Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PloS One. 8:e667822013. View Article : Google Scholar : PubMed/NCBI
16	Guo B, Liu L, Yao J, Ma R, Chang D, Li Z, Song T and Huang C: miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. Mol Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
17	Jin Y, Zhao M, Xie Q, Zhang H, Wang Q and Ma Q: MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4. Int J Oncol. 47:1594–1602. 2015. View Article : Google Scholar : PubMed/NCBI
18	Chen X, Ruan A, Wang X, Han W, Wang R, Lou N, Ruan H, Qiu B, Yang H and Zhang X: miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes. J Cancer Res Clin Oncol. 140:1295–1304. 2014. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Wang G and Sun Y, He Y, Ji C, Hu B and Sun Y: MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). Int J Clin Exp Pathol. 8:337–344. 2015.PubMed/NCBI
21	Huang N, Wu Z, Lin L, Zhou M, Wang L, Ma H, Xia J, Bin J, Liao Y and Liao W: miR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget. 6:15222–15234. 2015. View Article : Google Scholar : PubMed/NCBI
22	Han R, Huang S, Bao Y, Liu X, Peng X, Chen Z, Wang Q, Wang J, Zhang Q, Wang T, et al: Upregulation of SOX4 antagonizes cellular senescence in esophageal squamous cell carcinoma. Oncol Lett. 12:1367–1372. 2016.PubMed/NCBI
23	Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Zhang J and Han B: SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis. 16:301–307. 2013. View Article : Google Scholar : PubMed/NCBI
24	Lin CM, Fang CL, Hseu YC, Chen CL, Wang JW, Hsu SL, Tu MD, Hung ST, Tai C, Uen YH and Lin KY: Clinical and prognostic implications of transcription factor SOX4 in patients with colon cancer. PloS One. 8:e671282013. View Article : Google Scholar : PubMed/NCBI
25	Song GD, Sun Y, Shen H and Li W: SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients. Tumour Biol. 36:4167–4173. 2015. View Article : Google Scholar : PubMed/NCBI
26	Hur W, Rhim H, Jung CK, Kim JD, Bae SH, Jang JW, Yang JM, Oh ST, Kim DG, Wang HJ, et al: SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: Clinical implication and functional analysis in vitro. Carcinogenesis. 31:1298–1307. 2010. View Article : Google Scholar : PubMed/NCBI
27	Wang D, Hao T, Pan Y, Qian X and Zhou D: Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer. Mol Cell Biochem. 402:75–82. 2015. View Article : Google Scholar : PubMed/NCBI
28	Yu CC, Chen PN, Peng CY, Yu CH and Chou MY: Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits and lymph node metastasis. Oncotarget. 7:20180–20192. 2016. View Article : Google Scholar : PubMed/NCBI
29	Shi S, Cao X, Gu M, You B, Shan Y and You Y: Upregulated expression of SOX4 is associated with tumor growth and metastasis in nasopharyngeal carcinoma. Dis Markers. 2015:6581412015. View Article : Google Scholar : PubMed/NCBI
30	Parvani JG and Schiemann WP: Sox4, EMT programs, and the metastatic progression of breast cancers: Mastering the masters of EMT. Breast Cancer Res. 15:R722013. View Article : Google Scholar : PubMed/NCBI
31	Li Y, Chen P, Zu L, Liu B, Wang M and Zhou Q: MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4. Am J Cancer Res. 6:127–140. 2016.PubMed/NCBI